Background: A clinical diagnosis (CDx) of pancreatitis includes evaluation of clinical signs, abdominal ultrasound (AUS), and pancreatic lipase. However, practitioners are using AUS to diagnose pancreatitis and are using AUS severity to guide decisions.
| INTRODUCTION
Histopathology is the gold standard for the diagnosis of pancreatitis 1, 2 ; however, it is rarely performed due to its invasive nature and inherent limitations, including the potential to miss localized lesions or subclinical pancreatitis. 3, 4 Given these limitations, several recent studies have utilized a variety of data including clinicopathologic abnormalities, pancreatic ultrasound, and pancreatic lipase concentration (specific canine pancreatic lipase [Spec cPL]) as a surrogate gold standard for pancreatitis in dogs. [5] [6] [7] [8] [9] [10] Spec cPL is frequently utilized as it has the greatest sensitivity (21%-71%) and specificity (100%) for detection of histopathologic-confirmed pancreatitis. 11 Ultrasonographic findings consistent with acute pancreatitis include pancreatic enlargement, hypoechoic regions within the pancreas, increased echogenicity of the surrounding mesentery, altered pancreatic echotexture, and dilation of the pancreatic or biliary duct. [12] [13] [14] [15] Pancreatic cyst-like lesions also occur in the subacute phase of pancreatitis. 16 Other nonspecific changes include abdominal effusion, ileus, gastric wall thickening, and lateral displacement of the duodenum. 13, 15, 17 Anecdotally veterinary practitioners might use abdominal ultrasound (AUS) in conjunction with clinical signs and supportive clinical pathology screening, in the absence of a quantitative pancreatic lipase assay, for the diagnosis of pancreatitis and assessment of disease severity. In addition, although prior studies have documented potential ultrasonographic abnormalities seen with pancreatitis, the individual contribution of each abnormality to a CDx of pancreatitis in dogs has not been evaluated.
It has also been suggested that repeat AUS examinations can be used to monitor response to treatment, but in the absence of scientific study this remains controversial. 12 Clinical severity indices have been validated but it is currently unknown if ultrasonographic assessment of the severity of pancreatitis mirrors these indices. 18, 19 Therefore, the value of repeat AUS for monitoring of routine pancreatitis cases is unknown.
Although AUS is the imaging method of choice for pancreatitis, it is highly dependent on the skill and experience of the ultrasonographer and the equipment available. 20 Thus, ultrasonographer skill and ultrasound technology must be considered when evaluating prior studies. The sensitivity of AUS for detection of severe fatal pancreatitis was reported to be 68% in 1 study over 20 years ago. 13 Changes in ultrasound technology over the years might have increased the sensitivity, and caution has been advised to prevent the overinterpretation of ultrasonographic findings. 20 There were 5 objectives of this study. Firstly to determine if a correlation exists between AUS findings, pancreatic lipase concentration, and a CDx of pancreatitis in dogs. Secondly to determine if individual ultrasonographic abnormalities correlated more closely with a CDx of pancreatitis than others. Thirdly, to determine whether ultrasonographic assessment of the severity of pancreatitis mirrors clinical severity indices and fourthly to determine if changes in the ultrasonographic assessment of severity over time, in the same dog, mirror a change in Spec cPL concentration or change in CDx. The final objective was to calculate the sensitivity and specificity of modern AUS for the diagnosis of pancreatitis in dogs.
| MATERIALS AND METHODS

| Case selection and data collection
Cases were identified by searching the medical records at the authors' institution between June 2014 and June 2019. Criteria for inclusion in the study were dogs with clinical signs of gastrointestinal disease (eg, vomiting, diarrhea, anorexia, abdominal pain, lethargy, or a combination of these signs), in addition to having a Spec cPL and either a focal pancreatic ultrasound or a full AUS examination performed within 30 hours of each other. Thirty hours were selected to allow for emergency cases to be enrolled in the study. No other inclusion criteria were required.
| Spec cPL assay
Serum was submitted to a commercial laboratory (Texas A&M University, Gastrointestinal Laboratory, College Station, Texas) for the assessment of Spec cPL concentration at the time of sample collection. The Spec cPL is a diagnostic test that utilizes an ELISA for the quantification of canine pancreatic lipase. The Spec cPL assay is highly sensitive and specific for the diagnosis of clinical pancreatitis in dogs. 5, 7, 21 
| Ultrasonographic pancreatic assessment severity score
Abdominal ultrasound examinations were performed by either a radiology resident-in-training, under the supervision of a board-certified veterinary radiologist, or directly by a board-certified veterinary radiologist.
Ultrasonographic still images and video clips were later evaluated by a single-board certified veterinary radiologist (A.M.L.), who was blinded to case history and the results of diagnostic testing, including the Spec cPL assay. A single individual was used to retrospectively assess the images to prevent interobserver variation from impacting the data. The still images and video clips were assessed for evidence of pancreatic enlargement, echogenicity, and echotexture. Pancreatic enlargement was determined via comparison with previously published reference intervals, whereas pancreatic echotexture was a subjective measure as utilized in previous literature. [22] [23] [24] [25] The echogenicity of the pancreas was assessed via comparison with internal landmarks such as the surrounding mesentery, kidneys, spleen, and liver. The echogenicity of the surrounding mesentery and the presence of peripancreatic free fluid were also assessed.
The results of this retrospective evaluation were then used to assign an ultrasonographic pancreatic assessment severity score (UPASS), from 0 to 7, as outlined in Table 1 . The higher the UPASS, the greater the ultrasonographic evidence of pancreatitis and the greater the ultrasonographic severity of pancreatitis. Additional abnormalities such as pancreatic cysts or pseudocysts, pancreatic nodules, and pancreatic masses were recorded; however, they were not included in the UPASS. Twelve dogs had both an initial assessment and a later assessment by AUS; the change in UPASS for these dogs was calculated for further analysis. Two ultrasound machines were used during this retrospective study: Esaote Biosound MyLab 50 (Esaote North America Inc, Fishers, Indiana) and the Logiq s8 ultrasound machine (GE Healthcare, Madison, Wisconsin).
| Determination of a CDx of pancreatitis (clinical gold standard)
A CDx of pancreatitis was assigned to each dog by 1 of the authors after assessment of a comprehensive panel of information including the evaluation of the history, physical examination findings, clinicopathological data, and imaging findings of each dog at each visit.
| Clinical severity indices
In recent years, a number of clinical severity indices have been developed and validated for dogs admitted to intensive care units and in dogs with acute pancreatitis. Two such clinical severity indices include the acute patient physiologic and laboratory evaluation (APPLE) score and the canine acute pancreatitis severity (CAPS) score. 18, 19 Both the APPLE and CAPS scores were retrospectively calculated for each dog based on data collected at admission, with minor modification due to typical practices at the author's institution. For the modified CAPS, total calcium was utilized in place of ionized calcium (iCa) when the iCa was unavailable for review. For the modified APPLE score, lactate was included if performed at the time of presentation. If insufficient data were available, the modified APPLE and modified CAPS scores were not calculated for that visit (see Figure 1 ).
| Sensitivity and specificity of AUS for detection of clinical pancreatitis
The sensitivity and specificity of AUS for detection of pancreatitis were determined via comparison to a CDx of pancreatitis. The sensitivity and specificity were calculated under 3 sets of conditions. The first scenario was when only 1 of the following criteria was required for the diagnosis of pancreatitis, pancreatic enlargement, abnormal pancreatic echogenicity, or an abnormal mesenteric echogenicity. Secondly, when 2 of the criteria were required and thirdly when all 3 criteria were required for a diagnosis of pancreatitis. These components were chosen, as they were statistically significant when correlating individual components of the UPASS to CDx. Note: Table 1 denotes the components of the UPASS and their relative contributions to the UPASS. The UPASS ranges from 0 to 7, and the higher the UPASS the greater the ultrasonographic evidence of pancreatitis. Pancreatic enlargement was determined by comparison with the previously published reference intervals. 25 Pancreatic echotexture was subjectively assessed, and pancreatic echogenicity was determined by comparison to internal markers such as the kidney, liver, and spleen, 3 | RESULTS
| Statistical analysis
| Animals
A total of 176 client-owned dogs were initially identified; however, 19 dogs were subsequently excluded as the AUS and Spec cPL were performed >30 hours apart (n = 18) or incomplete medical records (n = 1), leaving 157 dogs, 12 of which were assessed on a second visit, for analysis (see Figure 1 ). Eighty-one were female (74 spayed females and 7 intact females), and 76 were male (65 neutered males and 11 intact males). The median age of dogs enrolled was 9 years (range, 4 months to 17 years and 6 months). The median weight of dogs enrolled was 8.8 kg (range, 1.02-60.0 kg).
| Spec cPL assay results
All samples were able to be measured. The median Spec cPL concentration was 140 μg/L (range, <30 to >2000 μg/L). Ninety-nine samples had a Spec cPL concentration <200 μg/L. Thirty-three samples had a Spec cPL concentration between 201 and 399 μg/L. Thirty-seven animals had a Spec cPL concentration ≥400 μg/L. Table 3 ). 
| Pancreatic ultrasound findings and UPASS
| Correlation between UPASS, Spec cPL concentration, and CDx
| Correlation between UPASS and clinical severity indices
| Association between changes in UPASS, Spec cPL, and CDx
| Sensitivity and specificity of AUS for detection of clinical pancreatitis
Three significant variables were included in the determination of sensitivity and specificity of AUS for clinical pancreatitis: pancreatic enlargement, pancreatic echogenicity, and the echogenicity of the surrounding mesentery. When only 1 of the criteria was required, the sensitivity and specificity of AUS for detection of pancreatitis was 89% (95% CI:
71.8%-97.7%) and 43% (95% CI: 34.0%-51.6%). When 2 criteria were required, the sensitivity and specificity were 78% (95% CI: 57.7%-91.4%) and 69% (95% CI: 60.3%-76.8%), respectively. When all 3 criteria were required, the sensitivity and specificity were 43% (95% CI: 24.5%-62.8%) and 92% (95% CI: 85.3%-95.7%), respectively.
| DISCUSSION
In this retrospective study, we evaluated the correlation between ultrasonographic evidence of pancreatitis, pancreatic lipase concentration, clinical severity indices, and a CDx of pancreatitis in 157 client-owned dogs. The results of this study highlight a discrepancy between AUS and pancreatic lipase concentrations in the diagnosis of pancreatitis in dogs, similar to previously reported. 36 This study also highlights a discrepancy between the ultrasonographic assessment of severity of pancreatitis and the validated clinical severity indices with only minor modifications. We also report the diagnostic sensitivity and specificity of modern AUS for the detection of pancreatitis in dogs using a variety of criteria. explanation for the lower correlation between UPASS and Spec cPL than between UPASS and CDx is that primary nonpancreatic diseases and steroid treatment have been associated with an above reference interval Spec cPL concentration, although the clinical relevance of these increases are often unknown. 21, [26] [27] [28] [29] [30] [31] [32] When evaluating individual components of the UPASS, this study . This is likely due to the fact that diseases other than pancreatitis cause pancreatic edema, including hypoalbuminemia and portal hypertension. 33 A significant correlation between peripancreatic free fluid and a diagnosis of pancreatitis was not established, this is also likely due to the many different etiologies for abdominal free fluid in dogs including, but not limited to, portal hypertension and hypoalbuminemia. The hyperechoic mesentery associated with pancreatitis, as demonstrated in this study and prior studies, might be due to extension of inflammation beyond the pancreas due to release of proinflammatory cytokines and fat saponification. 33 Pancreatic echotexture was also not significantly associated with a CDx of pancreatitis. This finding might instead, be related to disease severity, as an amorphous appearance to the pancreas is typically associated with pancreatic necrosis and hemorrhage. 33 Pancreatic echotexture is also a very subjective measurement when compared to pancreatic size, which has established reference intervals, and pancreatic echogenicity which can be compared to internal markers such as the liver, kidneys, and spleen.
The correlation between the ultrasonographic assessment of severity of pancreatitis, as measured by UPASS, and the validated clinical severity indices (with minor modifications) was evaluated. The first clinical severity index assessed was the APPLE, which was previously validated for use in dogs presenting to an intensive care unit and was independent of primary diagnosis. 18 In the prior study, both the APPLE full and APPLE fast scores were validated; however, a modified APPLE full score was utilized in this study, as the APPLE full score had a greater specificity than the APPLE fast score in the prior study. 18 The APPLE full score was retrospectively applied to the cases, with a minor modification in that lactate was not included if it was not performed at the time of presentation. No other variables were excluded. The second clinical severity index evaluated was the CAPS score, which was recently validated in dogs with acute pancreatitis. 19 Again, this score system was applied with minor modification, in that total calcium was utilized if an iCa was not performed. At the authors' institution, an iCa is typically performed only if the dog is displaying clinical signs of hypocalcemia or there is an abnormal total calcium concentration. We did not Table 3 denotes Spearman's rank correlation coefficient (r s value) and statistical significance (P value) for the correlation between ultrasonographic findings and a CDx of pancreatitis. An alpha level of .05 was used to determine statistical significance. *Statistically significant value. pancreatitis during initial analysis: pancreatic size, pancreatic echogenicity, and echogenicity of the surrounding mesentery. When only 1 criteria was required for a diagnosis of pancreatitis the sensitivity was high (89%) and the specificity was modest (43%). If 2 criteria were required, the sensitivity and specificity were both moderate at 78% and 69%, respectively. If pancreatic enlargement, a hypoechoic pancreas and a hyperechoic mesentery were all required, the specificity was excellent at 92%, but the sensitivity was significantly reduced at 42%. The sensitivity and specificities calculated in the current study differ from those reported 20 years ago which might be associated with advances in technology, as previously suspected, or due to differences in definitions for ultrasonographic evidence of pancreatitis. 13, 20 The presence of pancreatic enlargement in conjunction with an abnor- such studies have been performed in veterinary medicine, and to the authors' knowledge, the software has not been adapted for use in veterinary species. 35 A further potential limitation is the lack of histopathology in the cases evaluated. Despite histopathology being the historical gold standard, it has many limitations as previously discussed, and many recent studies have utilized a clinical gold standard for the diagnosis of pancreatitis. [5] [6] [7] [8] [9] [10] 
